$1000 Invested In This Stock Over The Last 15 Years, Would Be Worth This Much
West Pharmaceutical Servs (NYSE:WST) has outperformed the market over the past 15 years by 12.76% on an annualized basis.
Here’s How Much You Would Have Made Owning West Pharmaceutical Servs Stock In The Last 15 Years
West Pharmaceutical Servs (NYSE:WST) has outperformed the market over the past 15 years by 12.12% on an annualized basis.
When Winning Streaks Stop: Trying To Beat The Market By Buying Stocks Like Tesla
Teslas getting charged in a Wawa parking lot last month. Photo via author.
When Winning Streaks Stop
West Pharmaceutical Servs Q3 Adj. EPS $2.06 Beats $1.80 Estimate, Sales $706.50M Beat $687.09M Estimate
West Pharmaceutical Servs (NYSE:WST) reported quarterly earnings of $2.06 per share which beat the analyst consensus estimate of $1.80 by 14.44 percent. This is a 79.13 percent increase over earnings of $1.15 per share
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
West Pharmaceutical Servs’s Earnings: A Preview
West Pharmaceutical Servs (NYSE:WST) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.
Analysts estimate that West Pharmaceutical Servs will likely report an Earnings Per Share (EPS) of $1.80
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)